Healthcare resource utilization and costs associated with generalized myasthenia gravis: a retrospective matched cohort study using the National Health Insurance Research Database in Taiwan
Source : https://www.frontiersin.org/articles/10.3389/fneur.2023.1216595/full
BackgroundWe estimated healthcare resource utilization (HRU) and costs in patients with generalized myasthenia gravis (gMG) in Taiwan.MethodsThis retrospective population-based, matched cohort study used the National Health Insurance Research Database to...
Conclusion: gMG presents a substantial burden on HRU and healthcare costs in Taiwan. A high attrition rate from full-time employment suggests additional societal costs. Improved treatments are needed to alleviate the burden of disease on individuals, healthcare systems, and economies.
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
Source : https://www.frontiersin.org/articles/10.3389/fimmu.2023.1212757/full
Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to...
Conclusions/Relevance: This review aims to provide a detailed update on the pathomechanisms involved in MuSK-MG (cellular and humoral aberrations), fostering the understanding of the latest indications regarding the efficacy of different treatment strategies.
Clinical Characteristics of Myasthenia Gravis Patients with COVID-19 in Guangxi, China: A Case–Control Study
Describing clinical characteristics of myasthenia gravis (MG) patients with COVID-19 & identifying risk factors of exacerbation in MG patients with COVID-19.
Conclusion: MG patients with immunosuppressive drugs, younger onset, longer MG duration, or comorbidities are more susceptible to COVID-19. The baseline MG-ADL, duration of symptomatic COVID-19, GMG, and lack of COVID-19 vaccination are independent risk factors of exacerbation in MG patients with COVID-19.
Causal effect of vitamin D on myasthenia gravis: a two-sample Mendelian randomization study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37538922/
This study provides the causal relationship between genetically predicted circulating vitamin D levels and MG and provides new insights into the genetics of MG.
Conclusion: This study provides the causal relationship between genetically predicted circulating vitamin D levels and MG and provides new insights into the genetics of MG.
Dexamethasone improves thymoma-associated myasthenia gravis via the AKT-mTOR pathway - Naunyn-Schmiedeberg's Archives of Pharmacology
Source : https://link.springer.com/article/10.1007/s00210-023-02641-z
Clinically, thymoma patients are often complicated with myasthenia gravis (MG). Dexamethasone, a glucocorticoid with anti-inflammatory effects, could be used as an immunosuppressant for thymoma-associated MG, but the mechanism of action...
Conclusions/Relevance: This study demonstrates that dexamethasone can promote apoptosis through the AKT-mTOR pathway for the treatment of thymoma-associated MG, as validated by network pharmacology predictions and clinical specimen experiments, and can be verified by large-scale clinical trials in the future. This study also provides...